Canada - TSX Venture Exchange - TSX-V:TLT - CA88337V1004 - Common Stock
The current stock price of TLT.CA is 0.16 CAD. In the past year, price decreased by -38.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PRN.CA | PROFOUND MEDICAL CORP | N/A | 309.45M | ||
| MIR.CA | MEDMIRA INC | N/A | 56.87M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 48.44M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 35.69M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 20.12M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 19.69M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 19.10M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 18.04M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 2.84M | ||
| VER-H.CA | VERISANTE TECHNOLOGY INC | N/A | 659.10K | ||
| VVTM.CA | VVT MED INC | N/A | 19.38M |
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
THERALASE TECHNOLOGIES INC
41 Hollinger Road
TORONTO ONTARIO M4B 3G4 CA
CEO: Shawn Shirazi
Employees: 0
Phone: 14166995273
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
The current stock price of TLT.CA is 0.16 CAD. The price increased by 6.67% in the last trading session.
TLT.CA does not pay a dividend.
TLT.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TLT.CA.
The Revenue of THERALASE TECHNOLOGIES INC (TLT.CA) is expected to grow by 13.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a fundamental rating of 3 / 10 to TLT.CA. Both the profitability and financial health of TLT.CA have multiple concerns.
Over the last trailing twelve months TLT.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 23.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -144.9% | ||
| ROE | -398.4% | ||
| Debt/Equity | 0.19 |
9 analysts have analysed TLT.CA and the average price target is 0.71 CAD. This implies a price increase of 346.25% is expected in the next year compared to the current price of 0.16.
For the next year, analysts expect an EPS growth of -21.18% and a revenue growth 13.84% for TLT.CA